

The potential of three-dimensional printed stents in post-operative treatment of breast cancer

Junjuan Fan¹, Min Wang^{2,*}, Xianwen Wang^{2,*}

¹ Department of Pharmacy,
The Fourth Affiliated
Hospital of Soochow
University, Suzhou, Jiangsu
Province, China;

² School of Biomedical
Engineering, Anhui Medical
University, Hefei, Anhui
Province, China

***Corresponding authors:**

Min Wang,
minwang@ahmu.edu.cn;
Xianwen Wang,
xianwenwang@ahmu.edu.cn.

<http://doi.org/10.12336/biomatertransl.2024.03.010>

How to cite this article:

Fan, J.; Wang, M.; Wang, X. The potential of three-dimensional printed stents in post-operative treatment of breast cancer. *Biomater Transl.* 2024, 5(3), 331-333.



Breast cancer is among the most frequent cancers; it mostly strikes women and ranks second in female cancer fatality rates, behind only lung cancer.¹ There is a need to create efficient treatments to eradicate leftover tumor cells because, although surgery has been the predominant clinical treatment technique for cancer, local tumor recurrence and metastasis may still occur following surgery.² Typically prescribed as a neoadjuvant or auxiliary treatment to surgery, chemotherapy is a frequent and successful method of treating many cancer types.³ Systemic chemotherapy for breast cancer typically involves high dosages, which is associated with unpleasant side effects that are particularly noticeable, and chemotherapy treatment efficacy is poor. Chemotherapy resistance is easy to relapse.⁴ Based on patient requirements, local chemotherapy can help reconstruct after breast cancer surgery, which is one area where systemic chemotherapy falls short. The biomedical area, particularly medication distribution, has benefited greatly from the advancements made possible by three-dimensional (3D) printing technology, a relatively new manufacturing technique. The ability to quickly and precisely customise one-of-a-kind things is the main selling point of 3D printing.^{5,6}

In a recent paper published in *Carbohydrate Polymers*, Su et al.⁷ utilised a straightforward nanoprecipitation technique to create the nanotherapeutic medication carbon dots-curcumin nano-drug release from carbon dots and curcumin as inputs. By combining carbon dots-curcumin nanoparticles with chitosan, sodium alginate, and nanoclay, they created a novel local drug delivery system. The stent's luminescence performance and biocompatibility are both excellent. The 3D printed composite scaffold based on drug delivery scaffold (McF.7) not only considerably increased the tumor

suppression rate of breast cancer cells, but it also demonstrated this in the 14-day *in vitro* drug release assay. Its antimicrobial activity is also excellent in the long run. Furthermore, this scaffolds have demonstrated in animal studies that they may increase angiogenesis, decrease inflammation, and inhibit postoperative residual cancer cells when implanted in surgical defects. This allows for the repair of surgically-caused tissue abnormalities. Furthermore, there have been reports of 3D printing being used to treat breast cancer in other publications.^{4,8-11}

However, some concerns remain. Firstly, the biocompatibility and degradability of this material are important issues to be considered in practical applications. If the biocompatibility of the material is poor, it may lead to local inflammation or rejection, which will affect the therapeutic effect. In addition, if the degradation rate of the material is too fast or too slow, it may affect the release rate of the drug and the therapeutic effect. Second, the precise control of drug release is also a challenge. After breast cancer surgery, the physiological environment and drug requirements of local tissues can change, so there is a need for a stent that can precisely control the rate and dosage of drug release. However, current 3D printing technology may not yet be able to achieve this highly precision control.

3D printing was initially used for process optimisation and industrial prototyping and was developed from stereolithography in the late 1980s. With the development of various additive manufacturing, 3D printing has become more prominent in biomedical research and has gradually become an interdisciplinary research field for bioengineering and pharmaceutical majors. Proving the ability of 3D printing technology to provide complex and personalised dosage forms, Spritam[®] was the first 3D printed




Figure 1. Schematic diagram of CCNACA scaffolds for postoperative treatment of breast cancer and antibacterial performance evaluation. (A) Preparation of CDs and CCNPs. (B) Preparation of CCNACA scaffolds and their antibacterial properties *in vitro*. (C) Effects of CCNACA scaffolds on wound healing, tumour recurrence, and angiogenesis after tumour implantation in mice. Reprinted from Su et al.⁷ Copyright 2023 Published by Elsevier Ltd. CCNACA: a local drug delivery platform synthesised by CCNPs, sodium alginate, nanoclay and caffeic acid grafted chitosan; CCNP: carbon dots-curcumin nanoparticle; CD: carbon dot; ROS: reactive oxygen species.

drug approved by the U.S. Food and Drug Administration in 2015.¹² Based on these advantages, 3D printed polymer scaffolds for breast reconstruction and wound healing also offer great potential for the development of multi-functional implantable devices, ultimately enabling efficient and harmless cancer treatment. Despite the many advantages of using implantable drug delivery devices to treat breast cancer, they are still not used in clinical practice. The study shows that our experimental results are relevant to devices implemented in two-dimensional and 3D tumour models. So, need to further

study better animal models, such as animals and humanised mice immune function. In addition, more research is needed on the selection of materials. Getting the right material for implantable devices so that they do not cause adverse effects on the body, do not react with drugs, make the device easier to remove, or make the final device easily absorbed by the body remains a challenge. Therefore, the realisation of 3D printing implantable drug delivery devices has more profound significance in the accurate control of drug release dynamics, improved drug efficiency, and targeted drug delivery.

Author contributions

JF conceived and draft the manuscript; MW, and XW reviewed and edited the manuscript draft. Both authors approved the final version of the manuscript.

Financial support

This work was supported by the Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University (No. 2021xkjT028) and the Anhui Medical University Research Fund Youth Project (No. 2023xkj018).

Acknowledgement

None.

Conflicts of interest statement

The authors declare no conflicts of interest.

Open access statement

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

1. Pial, M. M. H.; Tomitaka, A.; Pala, N.; Roy, U. Implantable devices for the treatment of breast cancer. *J Nanotheranostics*. **2022**, *3*, 19-38.
2. Zhao, J.; Cui, W. Functional electrospun fibers for local therapy of cancer. *Adv Fiber Mater*. **2020**, *2*, 229-245.
3. Mazidi, Z.; Javanmardi, S.; Naghib, S. M.; Mohammadpour, Z. Smart stimuli-responsive implantable drug delivery systems for programmed and on-demand cancer treatment: an overview on the emerging materials. *Chem Eng J*. **2022**, *433*, 134569.
4. Hao, W.; Zheng, Z.; Zhu, L.; Pang, L.; Ma, J.; Zhu, S.; Du, L.; Jin, Y. 3D printing-based drug-loaded implanted prosthesis to prevent breast cancer recurrence post-conserving surgery. *Asian J Pharm Sci*. **2021**, *16*, 86-96.
5. Goyanes, A.; Det-Amornrat, U.; Wang, J.; Basit, A. W.; Gaisford, S. 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems. *J Control Release*. **2016**, *234*, 41-48.
6. Fu, J.; Yu, X.; Jin, Y. 3D printing of vaginal rings with personalized shapes for controlled release of progesterone. *Int J Pharm*. **2018**, *539*, 75-82.
7. Su, Y.; Liu, Y.; Hu, X.; Lu, Y.; Zhang, J.; Jin, W.; Liu, W.; Shu, Y.; Cheng, Y. Y.; Li, W.; Nie, Y.; Pan, B.; Song, K. Caffeic acid-grafted chitosan/sodium alginate/nanoclay-based multifunctional 3D-printed hybrid scaffolds for local drug release therapy after breast cancer surgery. *Carbohydr Polym*. **2024**, *324*, 121441.
8. Mu, X.; Zhang, J.; Jiang, Y. 3D printing in breast reconstruction: from bench to bed. *Front Surg*. **2021**, *8*, 641370.
9. Luo, Y.; Wei, X.; Wan, Y.; Lin, X.; Wang, Z.; Huang, P. 3D printing of hydrogel scaffolds for future application in photothermal therapy of breast cancer and tissue repair. *Acta Biomater*. **2019**, *92*, 37-47.
10. Shi, X.; Cheng, Y.; Wang, J.; Chen, H.; Wang, X.; Li, X.; Tan, W.; Tan, Z. 3D printed intelligent scaffold prevents recurrence and distal metastasis of breast cancer. *Theranostics*. **2020**, *10*, 10652-10664.
11. Zhao, P.; Wang, B.; Wang, L.; Fu, Z.; Hu, J.; Liu, Y.; Wang, J.; He, Y. Rapid printing of 3D porous scaffolds for breast reconstruction. *Bio-des Manuf*. **2023**, *6*, 691-703.
12. Wang, Y.; Sun, L.; Mei, Z.; Zhang, F.; He, M.; Fletcher, C.; Wang, F.; Yang, J.; Bi, D.; Jiang, Y.; Liu, P. 3D printed biodegradable implants as an individualized drug delivery system for local chemotherapy of osteosarcoma. *Mater Des*. **2020**, *186*, 108336.

Received: April 30, 2024

Revised: July 6, 2024

Accepted: September 24, 2024

Available online: September 28, 2024